Business, Liquidity and Capital Resources (Details) - USD ($)			1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 06, 2020	Jan. 09, 2020	Sep. 24, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Business, Liquidity and Capital Resources (Textual)
Cash and cash equivalents				$ 165,904,797		$ 165,904,797				$ 564,124
Net losses				(7,970,085)	$ (2,354,083)	(25,170,372)	$ (5,310,814)
Working capital				163,228,281		163,228,281
Stockholders' equity				194,625,763	284,908	194,625,763	284,908	$ 59,430,533	$ 64,741,841	$ (2,127,959)	$ 1,999,852	$ 3,326,065	$ 4,777,239
Net cash used in operating activities						(16,641,088)	(3,922,307)
Non stock based compensation				2,780,802	$ 139,140	7,407,331	318,484
Net of offering costs				$ 39,600,000		$ 39,600,000
Reverse stock split, description		1-for-40				On January 9, 2020, in connection with, and prior to the completion of the Merger, Protara Therapeutics, Inc. effected the Protara Reverse Stock Split, which resulted in 557,631 pre-merger shares of Protara Therapeutics, Inc. outstanding.
Private placement							$ 499,999
Gross proceeds			$ 147,600,000			$ 42,500,000
Net proceeds			$ 139,900,000
Subsequent Event [Member]
Business, Liquidity and Capital Resources (Textual)
Gross proceeds	$ 11,600,000
Net proceeds	$ 11,100,000